🔗 Permalink

Inventor profile of:

Eyal Breitbart

City:

Hashmonaim

Country:

Israel

Published Applications:

Last publication date:

2025-09-04

Top Assignees for applications by Eyal Breitbart

The entities that hold a legal rights for patent applications filed by inventor Breitbart Eyal:

Vascular Biogenics, Ltd. 32 Or Yehuda, Israel
Vascular Biogenics Ltd. 6 Modiin, Israel
ImmuneWalk Therapeutics, Inc. 2 Pearl River, NY United States
Vascular Biogenics Ltd. 2 , Israel
Vascular Biogenetics Ltd. 1 Modiin, Israel
Vascular Biogenics Ltd. 1 Or Yehuda, Ukraine
Vascular Biogenics Lts 1 Or Yehuda, Israel

Recent patent applications by Breitbart Eyal

Eyal Breitbart from Hashmonaim, IL has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2025-09-04

US20250277052A1

Chemistry; metallurgy

MOTILE SPERM DOMAIN CONTAINING PROTEIN 2, INTEGRIN BETA2 AND CD63

#2 | 2022-10-20

US20220331383A1

Human necessities

TREATMENT METHODS USING ADENOVIRUS

#3 | 2022-04-28

US20220127342A1

Chemistry; metallurgy

Motile sperm domain containing protein 2 antibodies and methods of use thereof

#4 | 2021-10-21

US20210322574A1

Human necessities

DIAGNOSTIC METHODS FOR ANTI-ANGIOGENIC AGENT THERAPY

#5 | 2021-04-01

US20210095044A1

Chemistry; metallurgy

Motile sperm domain containing protein 2 and cancer

#6 | 2021-03-18

US20210077622A1

Human necessities

Motile sperm domain containing protein 2 and inflammation

#7 | 2020-12-31

US20200407434A1

Chemistry; metallurgy

BISPECIFIC ANTIBODIES TO MOSPD2 AND T CELL- OR NK CELL-SPECIFIC MOLECULES

#8 | 2020-02-13

US20200046852A1

Human necessities

Methods of inducing responsiveness to anti-angiogenic agent

#9 | 2019-02-21

US20190054130A1

Human necessities

Treatment methods using adenovirus

#10 | 2019-02-07

US20190040150A1

Chemistry; metallurgy

Motile Sperm Domain Containing Protein 2 and Cancer

#11 | 2018-11-15

US20180325928A1

Human necessities

Oxidized lipids and treatment or prevention of fibrosis

#12 | 2018-08-02

US20180214543A1

Human necessities

Motile Sperm Domain Containing Protein 2 and Inflammation

#13 | 2017-12-28

US20170369516A1

Chemistry; metallurgy

Oxidized lipids and methods of use thereof

#14 | 2017-12-14

US20170354746A1

Human necessities

Methods of inducing responsiveness to anti-angiogenic agent

#15 | 2017-09-14

US20170258818A1

Human necessities

Oxidized lipids and treatment or prevention of fibrosis

#16 | 2016-10-20

US20160304544A1

Chemistry; metallurgy

Oxidized lipids

#17 | 2016-05-26

US20160143968A1

Human necessities

TREATMENT METHODS USING ADENOVIRUS

#18 | 2016-05-05

US20160121001A1

Human necessities

Methods of inducing responsiveness to anti-angiogenic agent

#19 | 2016-02-11

US20160038518A1

Human necessities

METHODS FOR TREATING PSORIASIS AND VASCULAR INFLAMMATION

#20 | 2016-01-14

US20160008381A1

Human necessities

Combined Treatment Utilizing VB-201

#21 | 2015-04-23

US20150111957A1

Chemistry; metallurgy

Endothelial cell-specific polynucleotides and use thereof

#22 | 2015-02-12

US20150044280A1

Chemistry; metallurgy

FAS-chimera adenovirus vector

#23 | 2014-06-05

US20140155467A1

Chemistry; metallurgy

PROMOTERS EXHIBITING ENDOTHELIAL CELL SPECIFICITY AND METHODS OF USING SAME FOR REGULATION OF ANGIOGENESIS

#24 | 2014-01-09

US20140010785A1

Chemistry; metallurgy

Methods for use of a specific anti-angiogenic adenoviral agent

#25 | 2013-11-14

US20130303595A1

Human necessities

Compositions and methods for treating glioblastoma GBM

#26 | 2013-11-07

US20130296404A1

Chemistry; metallurgy

Promoters exhibiting endothelial cell specificity and methods of using same

#27 | 2013-11-07

US20130295053A1

Chemistry; metallurgy

Methods of Producing Adenovirus Vectors and Viral Preparations Generated Thereby

#28 | 2013-10-24

US20130280217A1

Chemistry; metallurgy

Methods for Use of a Specific Anti-Angiogenic Adenoviral Agent

#29 | 2013-10-24

US20130280216A1

Chemistry; metallurgy

Methods for Use of a Specific Anti-Angiogenic Adenoviral Agent

#30 | 2013-10-17

US20130272998A1

Human necessities

Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulations of angiogenesis and anticancer therapy

#31 | 2013-08-29

US20130225525A1

Human necessities

Combined Treatment Utilizing VB-201

#32 | 2013-08-15

US20130209450A1

Human necessities

Compositions and Methods for Treating Glioblastoma GBM

#33 | 2013-08-08

US20130203707A1

Chemistry; metallurgy

Oxidized Lipid Compounds and Uses Thereof

#34 | 2013-07-04

US20130172294A1

Human necessities

Treatment with VB-201

#35 | 2013-02-28

US20130052165A1

Chemistry; metallurgy

Methods of Producing Adenovirus Vectors and Viral Preparations Generated Thereby

#36 | 2013-01-10

US20130011367A1

Chemistry; metallurgy

Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis

#37 | 2012-12-27

US20120329758A1

Human necessities

Combined Treatment Utilizing VB-201

#38 | 2012-08-09

US20120201790A1

Chemistry; metallurgy

Promoters exhibiting endothelial cell specificity and methods of using same

#39 | 2011-12-29

US20110319479A1

Chemistry; metallurgy

POLYPEPTIDES AND POLYNUCLEOTIDES ENCODING SAME AND USE THEREOF IN THE TREATMENT OF MEDICAL CONDITIONS ASSOCIATED WITH ISCHEMIA

#40 | 2011-10-13

US20110251122A1

Human necessities

Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy

#41 | 2011-09-22

US20110230450A1

Human necessities

PLATELET-ACTIVATING FACTOR (PAF) ANALOGS AND USES THEREOF

#42 | 2011-08-25

US20110207985A1

Chemistry; metallurgy

PROMOTERS EXHIBITING ENDOTHELIAL CELL SPECIFICITY AND METHODS OF USING SAME FOR REGULATION OF ANGIOGENESIS

#43 | 2011-08-25

US20110207703A1

Human necessities

Oxidized lipid compounds and uses thereof

#44 | 2011-08-18

US20110201677A1

Chemistry; metallurgy

PROMOTERS EXHIBITING ENDOTHELIAL CELL SPECIFICITY AND METHODS OF USING SAME

#45 | 2011-08-11

US20110195937A1

Chemistry; metallurgy

Oxidized thiophospholipid compounds and uses thereof

#46 | 2011-06-02

US20110129511A1

Chemistry; metallurgy

Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis

#47 | 2010-11-25

US20100298226A1

Chemistry; metallurgy

POLYPEPTIDES AND POLYNUCLEOTIDES ENCODING SAME AND USE THEREOF IN THE TREATMENT OF MEDICAL CONDITIONS ASSOCIATED WITH ISCHEMIA

#48 | 2010-11-11

US20100282634A1

Human necessities

Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis

#49 | 2010-04-01

US20100081193A1

Chemistry; metallurgy

Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis

#50 | 2009-12-31

US20090326052A1

Chemistry; metallurgy

Promoters exhibiting endothelial cell specificity and methods of using same

#51 | 2009-09-08

US10490746

Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy

#52 | 2009-03-12

US20090068207A1

Human necessities

Compositions Containing Beta 2-Glycoprotein I-Derived Peptides for the Prevention and/or Treatment of Vascular Disease

#53 | 2008-12-11

US20080305088A1

Human necessities

Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy

#54 | 2006-09-14

US20060204478A1

Human necessities

Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis

#55 | 2005-08-25

US20050186179A1

Chemistry; metallurgy

Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis

#56 | 2005-05-26

US20050112110A1

Chemistry; metallurgy

Promoters exhibiting endothelial cell specificity and methods of using same

InventorID:

26927 ⎘